Periprocedural Bleeding and 1-Year Outcome After Percutaneous Coronary Interventions Appropriateness of Including Bleeding as a Component of a Quadruple End Point by Ndrepepa, Gjin et al.
T
a
t
m
H
m
n
o
F
†
m
G
2
Journal of the American College of Cardiology Vol. 51, No. 7, 2008
© 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00
PCLINICAL RESEARCH Interventional Cardiology
Periprocedural Bleeding and 1-Year
Outcome After Percutaneous Coronary Interventions
Appropriateness of Including Bleeding
as a Component of a Quadruple End Point
Gjin Ndrepepa, MD,* Peter B. Berger, MD,† Julinda Mehilli, MD,* Melchior Seyfarth, MD,*
Franz-Josef Neumann, MD,‡ Albert Schömig, MD,*§ Adnan Kastrati, MD*
Munich and Bad Krozingen, Germany; and Danville, Pennsylvania
Objectives The aim of the study was to investigate the relationship between bleeding within the 30 days after percutaneous
coronary interventions (PCI) and 1-year mortality and to assess the appropriateness of inclusion of the periproce-
dural bleeding in a quadruple composite end point to assess PCI outcome.
Background Periprocedural bleeding is one of the most frequent complications of PCI.
Methods This study included 5,384 patients from 4 randomized placebo-controlled trials on the value of abciximab after
pre-treatment with 600 mg of clopidogrel: ISAR-REACT, -SWEET, -SMART-2, and –REACT-2. Bleeding—defined
according to the Thrombolysis In Myocardial Infarction criteria—included all bleeding events within 30 days after
enrollment. The primary end point was 1-year mortality.
Results In the 4 trials, within the first 30 days there were 42 deaths (0.8%), 314 myocardial infarctions (MIs) (5.8%),
52 urgent revascularizations (1.0%), and 215 bleeding complications (4.0%). Mortality at 1 year was 3.6% (n 
197). A Cox proportional hazards model revealed that the 30-day occurrence of bleeding (hazard ratio [HR] 2.96,
95% confidence interval [CI] 1.96 to 4.48; p  0.001), MI (HR 2.29, 95% CI 1.52 to 3.46; p  0.001) and urgent
revascularization (HR 2.49, 95% CI 1.16 to 5.35; p  0.019) independently predicted 1-year mortality. The c sta-
tistic was 0.79 for bleeding, 0.78 for MI, and 0.78 for urgent revascularization, demonstrating a comparable dis-
criminatory power of these adverse events for predicting 1-year mortality.
Conclusions Our study demonstrates a strong relationship between the 30-day frequency of bleeding and 1-year mortality
after PCI and supports the inclusion of periprocedural bleeding in a 30-day quadruple end point for the assess-
ment of outcome after PCI. (J Am Coll Cardiol 2008;51:690–7) © 2008 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.10.040w
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che selection of proper end points is critical for the
ssessment of the efficacy and safety of drugs or interven-
ional procedures (1). It is unanimously accepted that
ortality is the most important measure of clinical outcome.
See page 698
owever, in present-day interventional cardiology, total
ortality has become a relatively rare event, and large
umbers of patients would be required to assess the impact
f an investigational therapy on mortality. Inevitably, trials
rom the *Deutsches Herzzentrum, Technische Universität, Munich, Germany;
Geisinger Clinic, Danville, Pennsylvania; ‡Herz-Zentrum, Bad Krozingen, Ger-
any; and the §Medizinische Klinik rechts der Isar, Technische Universität, Munich,
ermany.c
Manuscript received July 31, 2007; revised manuscript received September 21,
007, accepted October 1, 2007.ith mortality as a primary end point will take longer to
omplete, which might delay treatment benefits to patients,
nd the regimen under consideration might become out-
ated during ongoing study, owing to potential surfacing of
ewly developed drugs and/or devices. Accordingly, com-
osite end points that include not only mortality but also
ther adverse events that occur more frequently are used to
ssess the safety and efficacy of novel percutaneous coronary
ntervention (PCI) therapies. The choice of which nonfatal
vents to include in a composite end point is usually
redicated on the assumption that the nonfatal adverse
vents are themselves associated with an increased risk of
eath (2). Traditionally, the composite end point of efficacy
sed to assess PCI procedures is the combined incidence of
eath, myocardial infarction (MI), and urgent repeat revas-
ularization of the target vessel at 30 days (3–6). Recently a
omposite end point that includes 30-day incidence of
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as been used. Termed a quadruple end point, because it
ncludes 4 components rather than the 3 components
raditionally included, this composite end point was used
n the REPLACE-2 (Randomized Evaluation in PCI
inking Angiomax to Reduced Clinical Events) trial to
ssess the outcome of patients undergoing a PCI procedure
7). A recent report from the REPLACE-2 trial has
emonstrated that major hemorrhage is an independent
redictor of 1-year mortality in patients undergoing elective
r urgent PCI (8). Data on the predictive power of bleeding
including minor bleeding) compared with MI or urgent
evascularization within 30 days after PCI, regarding 1-year
ortality and the appropriateness of including bleeding in a
0-day composite primary end point for the assessment of
CI outcomes, have not previously been addressed.
The aim of the present study was to investigate the
elationship between bleeding within 30 days after a PCI
rocedure and 1-year mortality and to assess the appropri-
teness of inclusion of the periprocedural bleeding in a
uadruple primary composite end point to assess the PCI
utcome.
ethods
he 4 trials included in this pooled analysis are the
SAR-REACT (Intracoronary Stenting and Antithrom-
otic Regimen-Rapid Early Action for Coronary Treat-
ent) (9), the ISAR-SWEET (Intracoronary Stenting and
ntithrombotic Regimen: Is Abciximab a Superior Way to
liminate Elevated Thrombotic Risk in Diabetics) (10), the
SAR-SMART (Intracoronary Stenting to Abrogate Reste-
osis in Small Arteries)-2 (11), and the ISAR-REACT-2
12). The 4 trials were performed between June 2000 and
ecember 2005.
These trials were considered together because of similar-
ties in the protocols regarding, among others, the anti-
hrombotic regimens used and the use of PCI. The inclu-
ion and exclusion criteria for the 4 trials have previously
een published in full (9–12). Briefly, all 4 ISAR trials were
andomized, placebo-controlled trials addressing whether
n added benefit exists from the glycoprotein IIb/IIIa
nhibitor abciximab in patients undergoing PCI after pre-
reatment with a 600-mg loading dose of clopidogrel. The
nclusion criteria common to all 4 trials were the presence of
oronary artery disease requiring a PCI procedure and
reatment with 600 mg of clopidogrel at least 2 h before the
oronary intervention. The ISAR-REACT trial recruited
atients at low-to-intermediate risk who underwent elective
CI. The ISAR-SMART-2 assessed the anti-restenotic
ffect of phosphorylcholine-coated stents and abciximab in
atients with small coronary artery disease (vessel size 2.5
m). The ISAR-SWEET trial enrolled diabetic patients
ho underwent an elective PCI, and the ISAR-REACT-2
rial recruited high-risk patients with non–ST-segment
levation acute coronary syndromes with or without an olevated troponin T. Excluded
rom the studies were patients
resenting with: an ST-segment
levation acute MI, hemody-
amic instability, in-stent reste-
osis, malignancies, increased
isk of bleeding (stroke within
he previous 3 months, active
leeding or bleeding diathesis,
ecent trauma or major surgery in
he last month, suspected aortic dissection), oral anticoag-
lation within 7 days, receipt of a glycoprotein IIb/IIIa
nhibitor within 14 days, high blood pressure (180 mm
g) unresponsive to therapy, a hemoglobin level 100 g/l
r hematocrit 34% or platelet count 100  109/l or
600  109/l, known allergy to the study medication,
regnancy (present or suspected), and reduced left ventric-
lar function with an ejection fraction 30%.
In all 4 trials, written informed consent was required for
articipation, and an institutional review board approved
ach study at all participating hospitals.
tudy protocol(s). Patients were randomized after the
ecision to perform a PCI was made but before the guide
ire had crossed the lesion in a double-blind manner with
ealed opaque envelopes containing the block randomiza-
ion sequence for each participating center. Patients in the
bciximab group received a bolus of abciximab 0.25 mg/kg
eight followed by an infusion of 0.125 g/kg/min (a
aximum of 10 g/min) for 12 h and a 70-U/kg bolus of
eparin intravenously. Patients in the placebo group re-
eived a bolus and a 12-h continuous infusion of placebo as
ell as a 140-U/kg bolus of intravenous heparin. Double-
linding was achieved by using similarly appearing vials in
he 2 groups of all 4 trials. No patients in any of the 4 trials
equired unblinding, and there were no crossovers.
Postinterventional antithrombotic therapy consisted of
spirin 100 to 325 mg indefinitely and clopidogrel 75 mg
wice daily for the remainder of the hospital stay up to 3
ays, followed by a recommendation of 75 mg/day for at
east 6 months. Other cardiac medications were prescribed
t the discretion of the patient’s physician. The local
esearch coordinators collected the data and forwarded them
o the data coordinating center. The quality of data collec-
ion was assessed by checking source documentation in
andom samples. Angiographic data were analyzed with the
ame Quantitative Angiographic Core Laboratory.
nd points, definitions, and follow-up. The primary end
oint of this analysis was 1-year mortality. The frequency of
ajor and minor bleeding both during the first 30 days was
efined with the Thrombolysis In Myocardial Infarction
TIMI) criteria (13). A bleeding complication was defined
s major if it was intracranial or if clinically overt signs of
emorrhage were associated with a drop in hemoglobin
oncentration of more than 5.0 g/dl (or, when a hemoglobin
alue was not available, an absolute drop in the hematocrit
Abbreviations
and Acronyms
CI  confidence interval
HR  hazard ratio
MI  myocardial infarction
OR  odds ratio
PCI  percutaneous
coronary interventionf at least 15%). Minor bleeding was defined as a clinically
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ted with a fall in hemoglobin concentration of 3.0 to 5.0
/dl (or, when a hemoglobin value was not available, a fall
n the hematocrit of 9 percentage points to 15 percentage
oints). A diagnosis of MI was based on the development of
ew abnormal Q waves in 2 contiguous precordial or 2
djacent limb leads or an elevation of creatine kinase-
yocardial band (CK-MB) (or total CK if CK-MB was not
vailable) 3 times the upper limit of normal. If the
re-PCI CK-MB (or total CK) was higher than the upper
imit of normal, both an increase by at least 50% over the
revious value and documentation that CK-MB (or total
K) had been decreasing before the suspected MI was
ecessary. If falling enzyme levels were not documented
efore the procedure, recurrent anginal symptoms or new
lectrocardiographic changes compatible with MI and a
K-MB elevation 50% above the peak level before
andomization for patients was required. In patients under-
oing coronary bypass surgery, a CK-MB 10 times the
pper limit of normal for patients was required to make a
iagnosis of procedural MI. Target vessel revascularization
as defined as coronary bypass surgery or repeat PCI
nvolving the target vessel performed in the presence of
ymptoms or signs of myocardial ischemia. All events were
djudicated and classified by an adjudication committee
linded to the assigned treatment.
All patients were either seen by their physician or
nterviewed by phone at 30 days, 6 months, and 1 year after
he procedure; patients with cardiac complaints underwent a
omplete clinical, electrocardiographic, and laboratory
heck-up.
tatistical analysis. The data are presented as median
25th, 75th percentiles] or as counts. The normality of
istribution was assessed with the 1-sample Kolmogorov-
mirnov test. Continuous data were compared with the
ilcoxon rank-sum test. Categorical data were compared
ith the chi-square test. One-year survival was estimated by
pplying the Kaplan-Meier method and log-rank test,
hich allowed the calculation of odds ratios (ORs) (95%
onfidence intervals [CIs]) associated with the 30-day
ccurrence of MI, urgent revascularization, or bleeding. The
ox proportional hazards model was used to test the
ssociation between bleeding, MI, and urgent revasculariza-
ion rates within 30 days after the PCI and 1-year mortality
hile adjusting for other confounding variables including
ge, gender, diabetes, arterial hypertension, hypercholester-
lemia, smoking, prior MI, prior coronary artery bypass
urgery, multivessel disease, duration of pre-treatment with
lopidogrel, elevated troponin (elevated or not), lesion
omplexity, left ventricular ejection fraction, baseline creat-
nine, and abciximab therapy. Sensitivity, specificity, and
ccuracy with respect to 1-year mortality were calculated for
I, urgent revascularization, and bleeding within 30 days
nd compared by the McNemar test. Discriminatory power
f the model with MI, urgent revascularization, or bleeding iithin 30 days included for 1-year mortality was assessed by
he c statistic (a c statistic of 0.5 indicates random prediction,
hereas a c of 1.0 indicates a perfectly discriminating
odel). All analyses were performed with the S-PLUS
tatistical package (Insightful Corp., Seattle, Washington).
p value 0.05 was considered to indicate statistical
ignificance.
esults
aseline characteristics. A total of 5,384 patients from 4
SAR trials were included in this study. There were 197
eaths (3.6%) within the first year after PCI. Table 1 shows
he baseline characteristics of patients who survived the first
ear after the PCI procedure and those who died during this
eriod. Patients who died had a worse cardiovascular risk
rofile than patients who survived the first year after the
CI procedure (Table 1), as would be expected. The 12-h
nfusion of abciximab was prematurely discontinued in 3
atients in the group of nonsurvivors (1.5%) and in 53
atients in the group of survivors (1.0%), p  0.50.
lopidogrel was prematurely discontinued within 30 days in
patients in the group of nonsurvivors (1.0 %) and in 25
atients in the group of survivors (0.5%); p  0.30.
elationship between individual components of the pri-
ary composite end point and 1-year mortality. At 30
ays, the frequency of individual components of the primary
omposite end point was as follows: death in 42 patients
0.8%), MI in 314 patients (5.8%), urgent revascularization
n 52 patients (1.0%), and bleeding in 215 patients (4.0%).
able 2 reveals the frequency of MI, urgent revasculariza-
ion, and bleeding within 30 days in patients who did or did
ot survive the first year. Stroke occurred in 11 patients
mong 1-year survivors (0.2%) and 2 patients (1.0%) among
onsurvivors (p  0.024).
The 1-year Kaplan-Meier estimate of mortality was
1.3% (n  35) among patients with an MI in the first 30
ays after enrollment versus 3.2% (n 162) among patients
ithout an MI within 30 days after PCI (OR 3.72, 95% CI
.64 to 5.22, p  0.001) (Fig. 1). There were 38 patients
ith Q-wave MI and 276 patients with non–Q-wave MI.
n patients with Q-wave MI, the 1-year estimate of mor-
ality was 29.0% (n  11) versus 3.2% (n  162) in patients
ithout any MI (OR 11.93, 95% CI 7.39 to 19.25; p 
.001). In patients with non–Q-wave MI, the 1-year esti-
ate of mortality was 8.7% (n  24) versus 3.2% (n  162)
n patients without any MI (OR 2.83, 95% CI 1.88 to 4.26;
 0.001). The 1-year estimate of mortality was 15.4%
n  8) among patients who needed urgent revascular-
zation versus 3.6% (n  189) among patients who did
ot undergo urgent revascularization procedures within
0 days of the index PCI (OR 4.74, 95% CI 2.49 to 8.99,
 0.001) (Fig. 2).
The 1-year mortality was 14.1% (n 30) among patientsn whom bleeding occurred within the 30 days after PCI
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February 19, 2008:690–7 Bleeding After Percutaneous Coronary Interventionersus 3.3% (n 167) among patients who had no bleeding
ithin the 30 days (OR 4.75, 95% CI 3.34 to 6.76, p 
.001) (Fig. 3). There were 59 patients with major bleeding
nd 156 patients with minor bleeding. In patients with
ajor bleeding, the 1-year estimate of mortality was 12.2%
OR 4.13, 95% CI 2.06 to 8.28; p  0.001 compared with
atients without bleeding). In patients with minor bleeding,
he 1-year estimate of mortality was 14.8% (OR 5.00, 95%
Demographic, Clinical, and AngiographicCharacteristics in 1-Ye r Survivors nd Nonsurv
Table 1 Demographic, Clinical, and AngiogrCharacteristics in 1-Year Survivors
Characteristics (n
Age (yrs) 66.3
Women 1
Body mass index (kg/m2) 26.9
Diabetes 1
Arterial hypertension 3
Current smoker
Hypercholesterolemia (240 mg/dl) 2
Previous myocardial infarction 1
Previous coronary artery bypass surgery
Acute coronary syndrome 1
Elevated troponin (0.03 g/l)
Elevated creatine kinase MB (24 U/l)
Serum creatinine (mg/dl) 1.0
Lesion location
Left main coronary artery
Left anterior descending coronary artery 2
Left circumflex coronary artery 1
Right coronary artery 1
Venous bypass graft
Multivessel disease 3
Complex lesions 3
Left ventricular ejection fraction (%) 59.0
Lesion length (mm) 11.8
Vessel size (mm) 2.75
Diameter stenosis (%) 64.4
Clopidogrel loading interval (h) 5.0
Type of intervention
Drug-eluting stent 1
Bare-metal stent 3
Balloon angioplasty
Abciximab therapy 2
Data are expressed as median [25th, 75th percentiles] or number of
0-Day Ischemic and Bleedingomplications n 1-Year Survivors and Nonsurvivors
Table 2 30-Day Ischemic and BleedingComplications in 1-Year Survivors and Nonsurvivors
Outcome
Survivors
(n  5,187)
Nonsurvivors
(n  197) p Value
MI 279 (5.4) 35 (17.8) 0.001
Urgent revascularization 44 (0.8) 8 (4.1) 0.001
Any bleeding 185 (3.6) 30 (15.2) 0.001
Major bleeding 52 (1.0) 7 (3.6) 0.001
Minor bleeding 133 (2.6) 23 (11.7) 0.001(
ata are expressed as number of patients (%).
MI  myocardial infarction.I 3.38 to 7.40; p  0.001 compared with patients without
leeding). No significant interactions were found regarding
-year mortality between bleeding and type of trial (p 
.45), between bleeding and abciximab use (p  0.64), and
etween bleeding and age (p  0.90).
At least 1 adverse event—urgent revascularization, MI,
r bleeding—was encountered in 501 patients (9.3%): ur-
ent revascularization (15 patients, 0.3%), MI (245 patients,
.5%), bleeding (169 patients, 3.1%), and more than 1 of
hese events (72 patients, 1.3%). In 4,883 patients, none of
hese adverse events occurred in the 30 days after PCI.
here were 2 deaths among patients requiring only urgent
evascularization (mortality estimate 13.3%, OR 5.17, 95%
I 1.48 to 18.06; p  0.001 compared with patients
ithout any adverse event in the 30 days after PCI), 22
eaths among patients with only MI (mortality estimate
.1%, OR 3.28, 95% CI 2.15 to 5.02; p  0.001 compared
ith patients without events within the first 30 days after
CI), and 21 deaths among patients with only bleeding
onsurvivors
ors
187)
Nonsurvivors
(n  197) p Value
, 73.8] 74.3 [67.7, 80.8] 0.001
4.5) 54 (27.4) 0.345
, 29.4] 25.7 [23.1, 29.1] 0.001
3.2) 95 (48.2) 0.001
0.1) 118 (59.9) 0.965
8.8) 34 (17.3) 0.596
6.8) 97 (49.2) 0.035
9.6) 80 (40.6) 0.001
0.1) 26 (13.2) 0.159
7.2) 94 (47.7) 0.002
8.9) 70 (35.5) 0.001
.3) 26 (13.2) 0.014
1.2] 1.2 [1.0, 1.5] 0.001
0.001
.7) 10 (5.1)
0.4) 86 (43.6)
7.9) 47 (23.9)
8.2) 43 (21.8)
.8) 11 (5.6)
5.9) 182 (92.4) 0.001
1.4) 138 (70.1) 0.670
, 65.0] 51.0 [36.0, 62.0] 0.001
16.6] 10.6 [6.8, 15.1] 0.001
, 3.14] 2.70 [2.33, 3.14] 0.187
, 75.0] 60.7 [52.7, 71.5] 0.020
12.0] 4.8 [2.5, 10.0] 0.147
0.193
1.5) 53 (26.9)
1.3) 132 (67.0)
.2) 12 (6.1)
0.1) 95 (48.2) 0.607
s (%).ivors
aphic
and N
Surviv
 5,
[59.3
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Bleeding After Percutaneous Coronary Intervention February 19, 2008:690–7 0.001 compared with patients without any adverse
vent in the 30 days after PCI). The remaining 13 deaths
18.0%) occurred in 72 patients who had suffered more than
adverse event within the first 30 days after PCI.
At 1 year, there were 58 deaths (11.6%) among patients
ho had suffered at least 1 of these events (n  501) in the
0 days after PCI versus 139 deaths (2.8%) among patients
ho had not (OR 4.46, 95% CI 3.23 to 6.16; p  0.001).
t 1 year there were 37 deaths (11.1%) among patients who
eeded urgent revascularization or had suffered an MI
ithin 30 days (n  332) versus 160 deaths (n  5,052;
.2%) among patients who had not (OR 3.83, 95% CI 2.62
o 5.58; p  0.001).
Figure 1 Post-Procedural Myocardial
Infarction and 1-Year Mortality
Kaplan-Meier curves of 1-year mortality among patients with and without myo-
cardial infarction within the first 30 days after the percutaneous coronary
intervention.
Figure 2 Post-Procedural Urgent
Reintervention and 1-Year Mortality
Kaplan-Meier curves of 1-year mortality among patients with and without urgent
reintervention within the first 30 days after the percutaneous coronary
intervention.*The impact of each ischemic or hemorrhagic complica-
ion within 30 days after PCI on mortality from 30 days to
year was also assessed. There were 155 deaths between 30
ays and 1 year (2.8%). Kaplan-Meier estimates of mortality
ere 6.4% (n  20) among patients who suffered an acute
I versus 2.7% (n  135) among patients without an MI
OR 2.58, 95% CI 1.64 to 4.05; p  0.001), 7.4% (n  16)
mong patients with bleeding versus 2.7% (n 139) among
atients without bleeding (OR 3.10, 95% CI 1.89 to 5.06;
 0.001) and 2.8% (n 152) among patients who needed
n urgent revascularization versus 5.8% (n  3) among
hose who did not undergo an urgent revascularization
ithin first 30 days after randomization (OR 2.25, 95% CI
.74 to 6.85; p  0.15).
ndependent predictors of 1-year mortality. The Cox
roportional hazards model was used to identify indepen-
ent predictors of 1-year mortality. The model included
I, urgent revascularization, and bleeding at 30 days as well
s the baseline characteristics (see Methods). Results of this
nalysis are shown in Table 3. It can be seen that bleeding
Figure 3 Post-Procedural Bleeding and 1-Year Mortality
Kaplan-Meier curves of 1-year mortality among patients with and without
periprocedural bleeding within the first 30 days after the percutaneous coro-
nary intervention.
ndependent Predictors of 1-Year Mortality
Table 3 Independent Predictors of 1-Year Mortality
Variable
Hazard Ratio
(95% Confidence Interval) p Value
Bleeding within 30 days 2.96 (1.96–4.48) 0.001
Myocardial infarction within 30 days 2.29 (1.52–3.46) 0.001
Urgent revascularization within 30 days 2.49 (1.16–5.35) 0.019
Age (yrs)* 2.27 (1.78–2.89) 0.001
Diabetes 1.47 (1.11–1.96) 0.008
Multivessel coronary disease 2.72 (1.58–4.67) 0.001
Elevated troponin 1.77 (1.27–2.47) 0.001
Left ventricular ejection fraction 0.71 (0.60–0.85) 0.001
Creatinine level† 1.10 (1.06–1.14) 0.001Calculated for a 10-year increase in age. †Calculated for a 0.25-mg increase in concentration.
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February 19, 2008:690–7 Bleeding After Percutaneous Coronary Interventionn the 30 days was 1 of the strongest independent predictors
f mortality at 1 year.
The impact of ischemic or hemorrhagic complications
ithin 30 days after PCI on 30-day to 1-year mortality was
lso tested in the Cox proportional hazards model, which
ncluded MI, urgent revascularization, and bleeding at 30
ays as well as the baseline characteristics (see preceding
ext). The model showed that bleeding (hazard ratio [HR]
.04, 95% CI 1.19 to 3.50; p  0.009) and MI (HR 1.96,
5% CI 1.18 to 3.26; p  0.01) but not urgent revascular-
zation (HR 1.49, 95% CI 0.45 to 4.91; p  0.51)
ndependently predicted 30-day to 1 year mortality.
Sensitivity, specificity, and accuracy of MI, urgent revas-
ularization, and bleeding within 30 days with respect to
-year mortality are shown in Table 4. Furthermore, pre-
ictivity of the models with MI, urgent revascularization, or
leeding regarding 1-year mortality was assessed by calcu-
ating the c statistic in the multivariable model including
ach of the components. The c statistic was 0.78 for MI,
.78 for urgent revascularization, and 0.79 for bleeding,
emonstrating a comparable discriminatory power of each
f the components. The univariate c statistic for a composite
f MI or urgent revascularization was 0.56. The univariate
statistic for a composite of MI, bleeding, or urgent
evascularization was 0.61. In the multivariable model, the c
tatistic was 0.78 for a composite end point of MI or urgent
evascularization and 0.80 for a composite end point of
rgent revascularization, MI, or bleeding.
iscussion
he main finding of this study is that bleeding in the 30
ays after a PCI is strongly associated with mortality as late
s 1 year after the procedure and that bleeding in the first 30
ays after a PCI is comparatively as strong as the 30-day
ccurrence of other adverse events such as MI or urgent
evascularization. This finding is particularly important,
ecause so many of the deaths in the first year (155 of 197
eaths, 79%) occurred more than 30 days after the proce-
ure and the time that the bleeding occurred. Importantly,
ur study showed that not only major but also minor
leeding was associated with late mortality.
Periprocedural bleeding is 1 of the most frequent com-
lications of PCI. Large registries of patients with coronary
rtery disease treated by PCI have reported an incidence of
ajor bleeding as high as 5.4%, close to the reported
ncidences of refractory ischemia, MI, or death (14). A
rowing body of evidence suggests that periprocedural
redictive Accuracy of MI, Urgent Revascularization, or Bleeding W
Table 4 Predictive Accuracy of MI, Urgent Revascularization, o
MI Urgent Revasculariza
Sensitivity 17.8 (35/197) 4.1 (8/197)
Specificity 94.6 (4,908/5,187) 99.1 (5,143/5,187
Accuracy 91.8 (4,943/5,384) 95.7 (5,151/5,384ata are expressed as % (n/N). *Bleeding versus myocardial infarction (MI). †Bleeding versus urgent rev
PCI  percutaneous coronary intervention.leeding in patients undergoing PCI is associated with an
ncreased risk of recurrent ischemic complications and that
leeding adversely affects both short-term (15–17) and
ong-term (8,18) mortality. A stepwise increase in the
0-day death, 30-day death or MI, and 6-month death with
ncreasing bleeding severity has been reported (15). The risk
f bleeding seems to be particularly high among patients of
lder age, women, patients with lower body weight, and
hose with impaired renal function, receiving multiple
ntithrombotic drugs, and those undergoing invasive pro-
edures (14,19–23). Advances in adjunct antithrombotic
herapy have reduced the incidence of thrombotic compli-
ations, but they have increased the risk of bleeding (24,25).
espite the frequent occurrence of bleeding and the poten-
ial that bleeding might adversely affect clinical outcome and
ven increase mortality, traditionally the outcome of PCI
rocedures in patients with coronary artery disease has been
ssessed by using the triple end point of death, MI, and
rgent repeat revascularization at 30 days (3–6). Bleeding
omplications have been either reported separately or ana-
yzed as component of a secondary end point, occasionally
eferred to as net clinical benefit (26).
The present pooled analysis of 4 ISAR trials captures a
ide range of patients with coronary artery disease, from
ower-risk patients undergoing elective PCI to higher-risk
atients with non–ST-segment elevation acute coronary
yndromes and MI. The analysis reveals that bleeding
ithin 30 days—nearly all of which was periprocedural
leeding—is 1 of the strongest predictors of 1-year mortal-
ty after PCI. Importantly, this study showed that not only
ajor bleeding but also minor bleeding was associated with
ncreased risk of death as long as 1 year after PCI. The most
mportant result of this study, however, is the finding that
eriprocedural bleeding is as strong a correlate of mortality
t 1 year as the components of the most commonly used
omposite end point in PCI studies, a 30-day occurrence of
I and urgent revascularization. Multivariable analysis
nequivocally demonstrated that periprocedural bleeding
ndependently correlates with 1-year mortality. The c sta-
istic shows that periprocedural bleeding (commonly
hought of as an index of safety) and MI or urgent
evascularization (commonly thought of as indexes of effi-
acy) have similar discriminatory power in predicting 1-year
ortality.
The inclusion of any event in a structure of a composite
nd point is generally based on the assumption that the
vent is associated with the outcome of primary interest
30 Days After PCI Regarding 1-Year Mortality
eding Within 30 Days After PCI Regarding 1-Year Mortality
Bleeding p Value* p Value†
15.2 (30/197) 0.46 0.001
96.4 (5,002/5,187) 0.001 0.001
93.4 (5,032/5,384) 0.001 0.001ithin
r Ble
tion
)
)ascularization.
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qual (or only slightly less) importance than other com-
onents (1,2,27,28). Our study suggests that periproce-
ural bleeding fulfills the aforementioned assumptions.
irst, as the present study and prior studies (8,18) show,
eriprocedural bleeding is strongly and independently
ssociated with 1-year mortality, even after adjustment
or other components of the composite end point (i.e.,
0-day MI and urgent revascularization). Periprocedural
leeding is at least as strong as MI as a prognostic factor.
hese data are in agreement with a recent report from the
CUITY (Acute Catheterization and Urgent Interven-
ion Triage strategy) trial, which showed that bleeding
as an even stronger correlate than MI of 30-day
ortality (17). Of note, our study did not evidence any
radient of importance between bleeding and other
omponents traditionally included in the structure of
omposite primary end point. Second, bleeding is a
elatively common event after PCI procedures, so its
nclusion in a primary end point reduces the sample size
equirements and increases the statistical power of a
tudy. The occurrence of bleeding is comparable in
requency to that of MI, which has traditionally been
ncluded in the primary composite end point to evaluate
he outcome of PCI (14,19). Third, there is a cause–
ffect relationship between the adjunctive therapies that
re being studied and bleeding complications (19,24,25).
In conclusion, our study found a strong and independent
elationship between bleeding early after a PCI procedure
nd mortality at 1 year, independent of baseline character-
stics measured and of the other components of the com-
osite end point traditionally used in evaluation trials of
ovel PCI therapies. This observation supports the inclu-
ion of bleeding in a 30-day quadruple primary end point
hat also includes death, MI, and urgent repeat revascular-
zation to assess the outcome of PCI procedures. Owing to
he strong and independent association between bleeding
fter a PCI and death, measures to reduce bleeding com-
lications should remain an important therapeutic goal.
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